Topics

VB-111 Hits Milestone in Phase III Platinum-Resistant Ovarian Cancer Trial

16:50 EDT 26 Mar 2020 | OncLive

An independent panel determined that the investigational agent VB-111 met the interim prespecified efficacy criterion in the phase III OVAL study in patients with platinum-resistant ovarian cancer, and that the trial should continue without modification.

Original Article: VB-111 Hits Milestone in Phase III Platinum-Resistant Ovarian Cancer Trial

NEXT ARTICLE

More From BioPortfolio on "VB-111 Hits Milestone in Phase III Platinum-Resistant Ovarian Cancer Trial"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...